Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.55, read 2026-11-03
Ethical does not pass the values gate
Price181.18 USD
Fair value271.18
Ethical score30.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution181.18+0.0% to today Accumulation gives way to Distribution
2026-10-22Read Accumulation176.20+2.8% to today ✓Markdown gives way to Accumulation
2026-10-17Read Markdown174.99+3.5% to today Accumulation gives way to Markdown first Markdown read since July
2026-10-16Read Accumulation174.99+3.5% to today ✓Distribution gives way to Accumulation while volume is distributing
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Enova International, Inc. holds its Distribution at $181.18. The statistical read favours the sellers, held for 13 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 13 days
Price at the screen
$181.18
Valuation
12.09 trailing · 8.21 forward price to earnings
Values screen
FAIL· score 30.0
Beta
1.39
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: financial services
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited keyword in sector/industry: financial services
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Enova International, does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ENVA's ethical verdict changes
Today ENVA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 35% discount to our $271.18 fair value, 36.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 33.2% discount to the base estimate.
Where our models see it going: fair-value estimate $271.18, with a range of $239.90 to $350.20, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Online Loans Hit the Ethical Wall
Picture a gig worker in Chicago needing cash before payday. Enova steps in with quick instalment loans and lines of credit across the US and Brazil. The numbers look solid on paper, with revenue rising 26 percent, a 21 percent profit margin and 25 percent return on equity at a forward multiple of 11.9 times.
We pass regardless. The business sits inside financial services, which trips our ethical screen outright. Opportunity rating sits at none even though the shares trade below our fair value estimate of 280 dollars from 232 dollars today. Strong buy analyst targets do not change that verdict.
High returns on equity often mask concentration in short term credit that can sour fast when rates or regulation shift. The ethical screen exists for exactly these cases. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ENVA trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. Insiders have been net sellers over the past quarter.
2026-10-29Accumulation$165.07-6.3%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$176.20+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$176.20+0.7%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$174.99+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$174.99+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown · changed$174.99+0.0%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Distribution$178.07+6.0%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 84%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it strong buy, with a mean price target of $202. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
